Paprotrain
| Code | Size | Price |
|---|
| AG-CR1-3504-M001 | 1 mg | £90.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
(Z)-alpha-(3-Pyridinylmethylene)-1H-indole-3-acetonitrile
Appearance:
Yellow solid.
CAS:
57046-73-8
EClass:
32160000
Form (Short):
solid
Handling Advice:
Protect from light.
InChi:
InChI=1S/C16H11N3/c17-9-13(8-12-4-3-7-18-10-12)15-11-19-16-6-2-1-5-14(15)16/h1-8,10-11,19H/b13-8+
InChiKey:
YMYYQRZCCKBFBE-MDWZMJQESA-N
Long Description:
Chemical. CAS: 57046-73-8. Formula: C16H11N3. MW: 245.3. Cell permeable and reversible kinesin-specific MKLP-2 (mitotic kinesin-like protein 2) inhibitor. Inhibits the recruitment of the chromosome passenger proteins survivin and aurora B to the central spindle during anaphase chromosome segregation. Moderate DYRK1A inhibitor (IC50= 5.5 µM). Lead compound.
MDL:
MFCD00617529
Molecular Formula:
C16H11N3
Molecular Weight:
245.3
Package Type:
Vial
Product Description:
Cell permeable and reversible kinesin-specific MKLP-2 (mitotic kinesin-like protein 2) inhibitor [1]. Inhibits the recruitment of the chromosome passenger proteins survivin and aurora B to the central spindle during anaphase chromosome segregation [1]. Moderate DYRK1A inhibitor (IC50= 5.5 µM). Lead compound [3].
Purity:
>98% (NMR)
SMILES:
[H]C(=C(C#N)C1=CNC2=C1C=CC=C2)C1=CN=CC=C1
Solubility Chemicals:
Soluble in DMSO (at least 5 mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Relocation of Aurora B and Survivin from Centromeres to the Central Spindle Impaired by a Kinesin-Specific MKLP-2 Inhibitor: S. Tcherniuk, et al.; Angew. Chem. (Int'l Ed.) 49, 8228 (2010) | New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations: C. Labri?re, et al.; Bioorg. Med. Chem. 24, 721 (2016) | Further investigation of paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors: C. Labri?re, et al.; Eur. J. Med. Chem. 124, 920 (2016)